Three-in-one erlotinib-modified NIR photosensitizer for fluorescence imaging and synergistic chemo-photodynamic therapy  

作　　者：Du Liu Yuyan Li Hankun Zhang Benhua Wang Chaoyi Yao Minhuan Lan Zhanhong Yang Xiangzhi Song 

机构地区：[1]College of Chemistry&Chemical Engineering,Central South University,Changsha 410083,China

出　　处：《Chinese Chemical Letters》2025年第2期295-299,共5页中国化学快报(英文版)

基　　金：supported by the National Natural Science Foundation of China(Nos.22278447 and 22178395);State Key Laboratory of Fine Chemicals(No.KF2109);State Key Laboratory of Chemo/Biosensing and Chemometrics(No.20230768)。

摘　　要：Photodynamic therapy(PDT)presents a promising avenue in cancer treatment.Erlotinib,an FDAapproved anticancer drug targeting epidermal growth factor receptor(EGFR),has shown effectiveness in normalizing tumor vasculature across various tumors,thereby promoting tumor oxygenation and facilitating PDT.In this work,erlotinib was conjugated with a near-infrared(NIR)photosensitizer,benzo[a]phenoselenazinium,yielding three EGFR-targeted PDT agents(NBSe-n C-Er).These newly synthesized photosensitizers demonstrate specificity in binding to EGFR,thereby enhancing their accumulation in cancer cells and tumors,and consequently improving the efficiency of both PDT and chemotherapy.Additionally,the NIR fluorescence emitted by the photosensitizer allows for imaging-guided therapy,offering a non-invasive means of monitoring treatment progress.The distinctive properties of the three-inone photosensitizer render it an ideal candidate for precise tumor treatment,overcoming the limitations of conventional therapies.

关 键 词：PHOTOSENSITIZER Benzo[a]phenoselenazinium Fluorescence imaging Photodynamic therapy Chemotherapy 

分 类 号：TQ422[化学工程] R730.5[医药卫生—肿瘤]